PTN

PTN

USD

Palatin Technologies Inc. Common Stock

$0.094-0.009 (-8.641%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$0.103

Máximo

$0.107

Mínimo

$0.087

Volume

0.34M

Fundamentos da empresa

Capitalização de mercado

2.4M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

1.77M

Bolsa de valores

ASE

Moeda

USD

Faixa de 52 semanas

Mínimo $0.035Atual $0.094Máximo $2.13

Notícias relacionadas

PR Newswire

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...

Ver mais
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
PR Newswire

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor...

Ver mais
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
PR Newswire

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Ver mais
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
PR Newswire

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Ver mais
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.